LOW POWER BRACHYTHERAPY IN COMBINED TREATMENT IN PATIENTS WITH INTERMEDIATE RISK OF LOCALIZED PROST ATE CANCER

Objective. Estimation of the effectiveness of low power brachytherapy sources I-125 in the combined treatment in group of patients of intermediate risk of localized prostate cancer.

Material and methods. The study included 126 patients with prostate cancer of intermediate risk. 104 patients (83,9%) were conducted low power brachytherapy I‑125 in combination with hormone therapy by analogues of LHWG. 22 patients (16.1%) received external beam irradiation in combination with brachytherapy I‑125 and hormonal treatment. Relapse-free survival of patients was evaluated in accordance with the criteria Phoenix (Nadir PSA + ng/ml). Evaluation of side effects of radiation treatment were carried out according to the RTOG criteria.

Results. PSA relapse-free survival in the group of brachytherapy and hormone treatment at the time of observation 5 years amounted to 97.1%. In the group of combined radiation therapy with brachytherapy, and hormonal treatment PSA relapse-free survival rate was 95.5%.In both groups, relapse-free survival was noted in 96,8% of cases. Tumor-specific and overall survival in both
groups was 100%. The major complications of treatment in both groups were radiation urethritis 1 to 2 degrees in 9.5% of cases (12 patients), urethral stricture in 5 patients (3.9% of cases), acute urinary retention in 1 patient (0.8% of cases) and late radiation rectitis of 2 degree in 1.58% of cases (2 patients).

Conclusions. It is possible to draw tentative conclusions about the high rate of survival without progression in both treatment groups on the background of the relatively low frequency of adverse reactions. It is necessary further follow-up for patients with estimating of survival for a longer period.

1. Novaja medicinskaja tehnologija. Brahiterapija (lokalizovannogo) raka predstatel’noj zhelezy. Avtory: Kaprin A. D., Pan’shin G. A., Al’bickij I. A. Milenin K. N., Cybul’skij A. D., Harchenko V. P. Razreshenija FS№ 2009/218 ot 27.07.2009 g.

2. Novaja medicinskaja tehnologija. Vnutritkanevaja luchevaja terapija (brahiterapija) raka predstatel’noj zhelezy. Avtory: Cyb A. F., Karjakin O. B., Birjukov V. A., Neledov D. V., Ruseckij S. S., Sviridov P. V., Panarina N. T., Volodina T. V., Oshhepkov V. N., Sivkov A. V. Razreshenija FS№ 2010/180 ot 17.05.2010 g.

3. Battermann J. J., Boon T. A., Moerland M. A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution [Journal]//RadiotherOncol. – 2004. – Vol. 71. – pp. 23–8.

4. Blasko J. C., Grimm P. D., Sylsvester J. E., Cavanagh W. The role of external beam radiotherapy with I‑125/Pd‑103 brachytherapy for prostate carcinoma [Journal]//RadiotherOncol. – 2000. – Vol. 57. – pp. 273–278.

5. Blasko J. C., Grimm P. D., Sylvester J. E. Palladium‑103 brachytherapy for prostate carcinoma [Journal]//Int J RadiatOncolBiolPhys. – 2000. – Vol. 46. – pp. 839–8350.

6. Critz F. A., Levinson K. 10‑year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology [Journal]//The Journal of Urology. – 2004. – Vol. 172. – pp. 2232–2238.

7. Dattoli M., Wallner K., Blasko J. Prostate Brachytherapy Made Complicated [Book]. – [s. l.]: Smart Medicine Press, 2001.

8. Dattol M., Wallner K., True L., Bostwick D. Long-term Outcomes for Patients with Prostate Cancer having Intermediate and High-risk Disease, treated with Brachytherapy and Supplemental External Beam Radiotherapy [Journal]//J Oncol. – 2010. – Vol. 2010. – p. 471375.

9. Davisetal B. J. American Brachytherapy Society consensus guidelines for transrectal ultrasound – guided permanent brachytherapy [Journal]//Brachytherapy. – 2012. – Vol. 11. – pp. 6–19.

10. Frank S. J. et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer [Journal]//Brachytherapy. – 2011. – Vol. 10. – pp. 357–62.

11. Grimm P. D., Blasko J. C., Sylvester J. E. Meier RM, Cavanagh W. 10‑year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy [Journal]//Int J RadiatOncolBiolPhys. – 2001. – Vol. 51. – pp. 31–40.

12. Heidenreich A. (chairman), Bastian P. J., Bellmunt J. et al. Guidelines on prostate cancer. [Online]//European Association of Urology Website. – 2012. – 10 17, 2014. – http://www. uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20II.pdf.

13. Lee L. N., Stock R. G., Stone N. N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation [Journal]// Int J RadiatOncolBiolPhys. – 2002. – Vol. 52. – pp. 444–452.

14. Merrick G. S., Butler W. M., Wallner K. E. et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy [Journal]//Int J RadiatOncolBiolPhys. – 2005. – Vol. 61. – pp. 32–43.

15. Merrick G. S. The role of hormonal therapy in prostate brachytherapy. Counterpoint [Journal]//Brachytherapy. – 2003. – Vol. 2. – pp. 2–4.

16. Potters L., Morgenstern C., Calugaru E. et al. 12‑year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer [Journal]//J Urol. – 2005. – Vol. 173. – pp. 1562–6.

17. Sohayda C., Kupelian P. A., Levin H. S. et al. Extent of extra- capsular extension in localized prostate cancer [Journal]//Urology. – 2000. – Vol. 55. – pp. 382–386.

18. Stock R. G., Cesaretti J. A., Stone N. N. Comparisons of PSA Failure Definitions Following Trimodality Therapy for Intermediate to High-Risk Prostate Cancer [Journal]//Int J RadiatOncolBiol- Phys. – 2007. – Vol. 69. – pp. S344‑S345.

19. Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to longterm outcome after prostate brachytherapy [Journal]//J Urol. – 2011. – Vol. 185. – pp. 495–500.

20. Teh B. S., Bastasch M. D., Mai W. Y. et al. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery [Journal]// Cancer J. – 2003. – Vol. 9. – pp. 454–460.

21. Vargas C., Swartz D., Vashi A. et al. Long-term outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy [Journal]//Brachytherapy. – 2013. – Vol. 12. – pp. 120–125.

22. Zelefsky M. J., Kuban D. A., Levy L. B. et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation [Journal]//International Journal of Radiation Oncology, Biology, Physics. – 2007. –Vol. 67. – pp. 327–333.